Intravesical Bacillus Calmette-Guérin versus mitomycin C for Ta and T1 bladder cancer-Reference-Cited by-同舟云学术

Intravesical Bacillus Calmette-Guérin versus mitomycin C for Ta and T1 bladder cancer

Published:2020-01-08 Issue: Volume: Page:
ISSN:1465-1858
Container-title:Cochrane Database of Systematic Reviews
language:en
Short-container-title:

Author:

Schmidt Stefanie¹,Kunath Frank¹²,Coles Bernadette³,Draeger Desiree Louise¹⁴,Krabbe Laura-Maria¹⁵,Dersch Rick⁶,Kilian Samuel⁷,Jensen Katrin⁷,Dahm Philipp⁸⁹,Meerpohl Joerg J¹⁰

Affiliation:

1. UroEvidence@Deutsche Gesellschaft für Urologie; Martin-Buber-Str. 10 Berlin Germany 14163

2. University Hospital Erlangen; Department of Urology; Krankenhausstrasse 12 Erlangen Germany 91054

3. Cardiff University Library Services; Velindre NHS Trust; Velindre Cancer Centre Whitchurch Cardiff UK CF14 2TL

4. University of Rostock; Department of Urology; Ernst-Heydemann-Strasse 7 Rostock Mecklenburg-Vorpommern Germany 18057

5. University of Muenster Medical Center; Department of Urology; Albert-Schweitzer Campus 1, GB A1 Muenster NRW Germany 48149

6. Medical Center - University of Freiburg; Department of Neurology and Neurophysiology; Berliner Allee 29 Freiburg Germany 79110

7. University of Heidelberg; Institute of Medical Biometry and Informatics; Heidelberg Germany

8. Minneapolis VA Health Care System; Urology Section; One Veterans Drive Mail Code 112D Minneapolis Minnesota USA 55417

9. University of Minnesota; Department of Urology; 420 Delaware Street SE MMC 394 Minneapolis Minnesota USA 55455

10. Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg; Institute for Evidence in Medicine; Breisacher Str. 153 Freiburg Germany D-79110

Publisher

Wiley

Subject

Pharmacology (medical)

Link

https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011935.pub2/epdf/full

Reference204 articles.

1. Intravesical electromotive mitomycin C versus passive transport mitomycin C for high risk superficial bladder cancer: a prospective randomized study;Stasi;Journal of Urology,2003

2. Long-term intravesical adjuvant chemotherapy further reduces recurrence rate compared with short-term intravesical chemotherapy and short-term therapy with Bacillus Calmette-Guérin (BCG) in patients with non-muscle-invasive bladder carcinoma;Friedrich;European Urology,2007

3. Comparison of the effectiveness between long-term instillation of mitomycin C and short-term prophylaxis with MMC or bacille Calmette-Guérin. Study of patients with non-muscle-invasive urothelial cancer of the urinary bladder;Isbarn;Urologe,2008

4. A randomized multicenter trial of adjuvant therapy in superficial bladder cancer: transurethral resection only versus transurethral resection plus mitomycin C versus transurethral resection plus Bacillus Calmette-Guerin;Krege;Journal of Urology,1996

5. Randomized intergroup comparison of Bacillus Calmette-Guerin immunotherapy and mitomycin C chemotherapy prophylaxis in superficial transitional cell carcinoma of the bladder a southwest oncology group study;Lamm;Urologic Oncology,1995

Cited by 44 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Signal mining and gender differences analysis of adverse events in NMIBC treatment with gemcitabine and BCG bladder instillation based on the FAERS database;Expert Opinion on Drug Safety;2024-08-08

2. Preoperative blood-based nutritional biomarkers as significant prognostic factors after intravesical BCG therapy in patients with non-muscle-invasive bladder cancer;World Journal of Urology;2024-07-22

3. Contemporary Treatment of NMIBC—Is It Time to Move on from BCG?;Journal of Clinical Medicine;2024-07-14

4. BCG and bladder cancer. Forty-eight years after Morales report;Urologia Journal;2024-05-17

5. Documento multidisciplinar de consenso sobre el tratamiento actual del tumor vesical no-músculo invasor que no responde al tratamiento con bacilo Calmette-Guérin;Actas Urológicas Españolas;2024-05